Background: Early restoration of blood flow of the infarct-related artery is associated with an improved outcome in patients with ST-elevation myocardial infarction (STEMI). Previous studies have shown a low mortality in patients with TIMI 3 flow before primary percutaneous coronary intervention (PCI). Most likely these patients had spontaneous recanalization of the infarct vessel and might constitute a low-risk subgroup. The purpose of the present analysis was to investigate whether TIMI 3 flow obtained with fibrinolysis before PCI is associated with a clinical outcome comparable to that in patients with spontaneous TIMI 3 flow. Methods: Patients with STEMI <6 hours enrolled in the ASSENT-4 PCI study were randomized to facilitated PCI with tenecteplase or primary PCI. For this analysis, patients were divided into three groups according to the TIMI flow of the infarct vessel before PCI: TIMI 0/1, TIMI 2, and TIMI 3. Results: From a total of 1617 patients, 861 had TIMI 0/1, 279 had TIMI 2, and 477 TIMI 3 flow. The rates of TIMI 3 flow after PCI were 84.6, 89.7, and 95.6%, respectively. Complete ST resolution was observed most often in the TIMI 3 flow group (47.5, 53.6, and 58.6%). The incidence of cardiogenic shock (6.2, 5.5, and 3.6%) and 90-day mortality (6.1, 4.7, and 4.0%) were lowest in the group with TIMI 3 patency before PCI, respectively. The rate of TIMI 3 flow before PCI was higher in the facilitated PCI group than in the primary PCI group (43.9 vs. 15.2%). The 90-day mortality in patients with TIMI 3 before PCI was identical in the facilitated and the primary PCI groups (14/353, 4.0% vs. 5/124, 4.0%). Conclusion: In this post-hoc analysis of ASSENT-4 PCI, TIMI grade 3 flow in the infarct-related artery before PCI, occurring either spontaneously or obtained by fibrinolysis, is associated with a higher TIMI patency after PCI, better improved ST resolution and a trend towards a favourable clinical outcome after 90 days.
Introduction
In patients with acute ST-segment elevation myocardial infarction rapid restoration of blood flow in the infarct-related coronary artery is associated with an improved prognosis. 1 One major component of the success of reperfusion therapy is the total ischaemic time. 2−4 Primary percutaneous coronary intervention (PCI) is the preferred treatment in patients with acute ST-elevation myocardial infarction (STEMI), provided it can be undertaken with minimal delay by an experienced team following presentation. 5 This strategy is limited, however, by time delays including those imposed by transferring patients to PCI-capable facilities. 6 Establishing early pharmacological reperfusion prior to mechanical intervention has the potential to overcome these time-dependent limitations of primary PCI and thereby improve both procedural success and clinical outcomes. 7 Previous studies report an improved outcome in patients with primary PCI with TIMI 3 patency prior to the intervention. 8, 9 These patients might constitute a special subgroup without persistent occlusion. The aim of this analysis was to compare the fate of patients with TIMI 3 patency before primary PCI occurring either spontaneous or associated with fibrinolysis.
Methods
The details of the ASSENT-4 PCI study have been published previously. 10 In brief, 1667 patients with ST-segment elevation acute myocardial infarction of less than 6 hours, scheduled to undergo primary PCI were randomized to a standard PCI procedure or one preceded by full-dose tenecteplase administration (facilitated PCI). The investigators had initially planned to enrol 4000 patients; however, the data and safety monitoring board recommended early cessation of enrolment because of higher in-hospital mortality in the facilitated PCI group. ECG criteria for entry required total ST-segment elevations of ≥0.6 mV across multiple leads or, for inferior infarction, ≥0.6 mV ST-segment deviation with at least 0.4 mV of ST-elevation in leads II, III, aVF, or new left bundle branch block with concordant ST-segment elevation ≥0.1 mV.
For this analysis, we created subgroups of patients according to the TIMI flow 11 in the infarct-related coronary artery as assessed by the investigators.
Electrocardiographic analysis
The amount of ST-segment elevation was measured at the J point with magnified callipers from leads I, aVL, and V1−V6 for anterior myocardial infarction and leads II, III, aVF, V5, and V6 for inferior MI. For the total ST-segment deviation, the sum of the ST-segment depression in leads II, III, and aVF for anterior and that in V1−V4 for inferior myocardial infarction were added. The resolution of ST-segment elevation (or total deviation if present) at 60 min and 180 min was classified according to the Schroder's method: 12 complete (i.e. resolution of the initial sum of ST-segment elevation ≥70%), partial (i.e. ST-segment resolution <70% to 30%), and none (i.e., ST-segment resolution <30%). Electrocardiographic spontaneous reperfusion was defined as those patients who achieved complete (≥70%) ST-segment resolution.
Statistical analysis
Descriptive statistics were summarized as medians with 25th and 75th percentiles for continuous variables and the Mann−Whitney U-test or Kruskal−Wallis test was used for group comparisons, where appropriate. The groups were compared with the Chi-squared test for categorical variables (%). A multivariate logistic regression, using backward stepwise variable selection procedures, was used to assess the independent prognostic value of TIMI 3 patency for 90-day mortality adjusted for key risk factors including age, sex, diabetes, systolic blood pressure, heart rate, location of infarction, Killip class, and time from onset of symptoms to treatment. All tests were two-sided, with a 5% level of significance. All analyses were performed using SPSS (version 16).
Results
A total of 1667 patients were included in ASSENT-4 PCI. Angiographic data were available from 1617 patients, of whom 861 (53.2%) had TIMI 0/1, 279 (17.3%) had TIMI 2, and 477 (29.5%) TIMI 3 flow at the initial angiography. The baseline variables of the groups according to the TIMI flow prior to PCI are shown in Table 1 . There were no clinical relevant differences between the three groups, except for the incidence of Killip class, showing a higher rate of Killip class I in the group with TIMI 3 flow prior to PCI.
We observed a higher rate of TIMI 3 flow after PCI in the group with TIMI 3 flow before PCI. In addition, the incidence of complete ST resolution was higher in these patients both before and after PCI ( Table 2 ). The mortality ( Figure 1 ) and combined clinical event rates after 30 and 90 days ( Table 2 ) tended to be lower in the group with TIMI 3 flow before PCI, but the differences were not statistically significant. In the multivariate analysis, TIMI 3 flow before PCI was not an independent predictor of 90-day survival. At 30 days the clinical endpoints tended to better outcomes in patients with TIMI 2 or 3 flow, and at 90 days (the principal time point for the trial endpoint analysis in ASSENT 4 PCI) the lowest mortality, incidence of shock, heart failure, and the combined endpoints were observed in patients with pre-PCI TIMI 3, but the differences did not achieve statistical significance. At 90 days, Patients with a patent vessel (TIMI 2/3, n=756) before angiography had a lower mortality (4.2 vs. 6.1%, p=0.1) and combined primary endpoint (mortality, shock, and congestive heart failure) of 14.0 vs. 16 .2% (p=0.2) compared to patients with an occluded artery (TIMI 0/1) before PCI. Again the differences were statistically not significant. The incidence of TIMI 3 flow was higher in the group with facilitated PCI (43.9 vs. 15.2%).
Patients then were divided into four groups according to their treatment and TIMI flow before PCI. The baseline variables of the four groups are listed in Table 3 and the clinical outcomes and events are listed in Table 4 . We observed no difference in outcome in patients with TIMI 3 flow prior PCI between the facilitated PCI and primary PCI group (Table 4, Figure 2 ). In contrast, the mortality and combined endpoint rates at 30 days were higher in patients with TIMI <3 flow before PCI treated with tenecteplase compared to patients with primary PCI (Table 4, Figure 2 ). The lowest event rate was observed in patients with a time interval of <3 hours between symptom onset and randomization and TIMI 3 flow before PCI (Table 5 ).
Discussion
Primary PCI is the preferred reperfusion therapy in patients with STEMI, if it can be provided by an experienced team within 2 hours after first medical contact. 13 Previous reports have shown a higher success rate of primary PCI and a lower mortality in patients with TIMI 3 flow before PCI. 8, 9 Our analysis is the first to investigate the influence of TIMI 3 flow mediated by fibrinolysis on outcome of patients with PCI for acute ST-elevation myocardial infarction. In previous studies, the rate of TIMI 3 flow before primary PCI occurring spontaneously or mediated by heparin, aspirin, and clopidogrel has been found to be around 15−20%. 14 In a meta-analysis of the PAMI trials, TIMI 3 flow before primary PCI was observed in 15.7% of the patients. 8 These patients had a higher rate of TIMI 3 flow after PCI, which was 98.1 vs. 91.4% in patients with TIMI 0−2 flow before PCI. This was associated with a very low mortality of 0.5% after 6 months while the 4.4% mortality in patients with an occluded infarct vessel before PCI was significantly higher. However, in ASSENT-4 PCI, the 90-day mortality in patients with TIMI 3 flow before PCI was 4.0, which is higher than the mortality in those patients in the PAMI trials. This may reflect the design of ASSENT-4 PCI which purposefully recruited higher risk patients. However, in a retrospective analysis the benefit of facilitated PCI in the FINESSE trial has been observed only in patients with higher baseline risk. 15 As in the PAMI meta-analysis in our study, patients with TIMI 3 flow before PCI had the lowest mortality. There was no difference in mortality between patients with TIMI 3 flow occurring spontaneously or mediated by fibrinolysis. In addition we observed comparable rates of TMI 3 flow after PCI and successful myocardial reperfusion rates assessed by complete ST resolution in patients with TIMI 3 flow before PCI in the primary PCI and facilitated PCI groups. Pre-PCI TIMI 3 flow was strongly associated with complete resolution of ST-segment elevation before intervention. After PCI, complete ST-segment resolution was again commonest in the pre-PCI TIMI 3 group. Complete resolution is generally accepted as evidence for myocardial salvage and therefore might predict improved clinical outcome. 12 In a separate analysis of ASSENT-4 PCI spontaneous reperfusion assessed in a subgroup of 585 patients, spontaneous reperfusion determined by ST resolution was a stronger predictor of an improved outcome compared to TIMI 3 flow. 16 In our analysis, mortality, shock, heart failure, and the combined endpoint were all lower with pre-PCI TIMI 3 but the differences did not reach statistical significance. However, in contrast to previous reports, TIMI 3 flow before PCI was not an independent predictor of survival. The reason might be related to the limited number of patients in our analysis, but is most likely due to the unexpected high mortality in the patients with TIMI 3 flow. In disagreement with earlier reports, the 90-day mortality in patients with TIMI 3 flow before PCI in the primary PCI group was found to be almost similar to that of patients with TIMI 2 flow (4.0 vs. 4.5%). One interesting finding was that patients with TIMI 0−2 flow in the facilitated PCI group had a higher mortality than patients with TIMI 0−2 flow in the primary PCI group (7.6% vs. 4.5%). These patients had the lowest TIMI 3 flow rate after PCI (82.9%) and the highest 90-day composite endpoint rate of 21.2%. These results imply a negative impact of failed fibrinolysis on outcome of facilitated PCI. Therefore the positive effect of an increased rate of patent infarct vessels before PCI might be counterbalanced by the negative impact of failed fibrinolysis on PCI. Other approaches than fibrinolysis to improve patency of the infarct vessel before primary PCI include glycoprotein IIb/IIIa inhibitors and ADP-receptor blockers. In the EGYPT meta-analysis, early initiation of glycoprotein IIb/ IIIa inhibitors before primary PCI significantly increased TIMI 3 patency. 14 In the randomized On-TIME 2 study, especially patients with longer transportation times had benefit from pre-hospital administration of tirofiban. 17 The only randomized trial investigating the value of prehospital administration of clopidogrel before primary PCI showed only a modest increase of TIMI 3 patency compared to standard therapy. 18 However the time between the clopidogrel loading dose and angiography was only 47 min, so clopidogrel had little chance to be metabolized and effectively inhibit platelet aggregation. It might be speculated that the new ADP-receptor antagonists parasugrel and ticagrelor will be more effective in this setting.
In summary, in this post-hoc analysis of ASSENT-4 PCI, TIMI grade 3 flow in the infarct-related artery before PCI, occurring either spontaneously or obtained by fibrinolysis, is associated with a higher TIMI patency after PCI, better improved ST resolution, and a trend towards a favourable clinical outcome after 90 days. Therefore effective and safe approaches to increase pre-PCI TIMI 3 flow should be investigated. 
